Mednet Logo

How would you manage a patient with metastatic HCC on atezolizumab/bevacizumab who requires holding bevacizumab due to persistent proteinuria >2g?

Do you continue atezo alone if responding or switch to an alternative therapy such as dual IO or TKI? What about if the patient were experiencing subtle progression due to holding bevacizumab?
Community PollStarted

How do you manage grade 2 or higher proteinuria in patients treated with atezolizumab/bevacizumab for HCC?

38 physicians have voted

Join Mednetto vote and see how they answered.

2 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic, Rochester
Answered on

This is a great clinical question, one that we often see since the approval of atezolizumab/bevacizumab in first line setting for HCC.

Incidence of proteinuria with bevacizumab has been reported anywhere from 0.8%-4% for grade 3 (more than 3.5 g in a 24-hour urine protein level) (Brandes et al., PMI...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of Virginia
Answered on

If no progression and good tolerance of single agent atezo, would continue atezo. Would also investigate other possibilities for proteinuria and often start ACEI/ARB which may improve to 1+ and can consider resuming bev in that context.

If progressing on single agent atezo, little data or expectati...

Join for free or sign in to see the full answer